These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39069202)

  • 21. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
    Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; van Wezel T; van Eijk R; Ruano D; Tensen CP; Hauben E; Woei-A-Jin FJSH; Busschots AM; van den Berg A; Diepstra A; Vermeer MH; Vermaat JSP
    Virchows Arch; 2022 Mar; 480(3):667-675. PubMed ID: 35028710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
    Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
    J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation.
    Song Y; Cao Z; Li L; Zhang HT; Zhang X
    Chin J Cancer; 2010 Sep; 29(9):781-6. PubMed ID: 20800019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.
    Gualco G; Weiss LM; Harrington WJ; Bacchi CE
    Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.
    Wawire J; Sayed S; Moloo Z; Sohani AR
    J Glob Oncol; 2019 May; 5():1-8. PubMed ID: 31045473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
    Yin HF; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 39(2):158-62. PubMed ID: 17440591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
    Frauenfeld L; Castrejon-de-Anta N; Ramis-Zaldivar JE; Streich S; Salmerón-Villalobos J; Otto F; Mayer AK; Steinhilber J; Pinyol M; Mankel B; Ramsower C; Bonzheim I; Fend F; Rimsza LM; Salaverria I; Campo E; Balagué O; Quintanilla-Martinez L
    Blood Adv; 2022 Apr; 6(7):2361-2372. PubMed ID: 34654055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival.
    Dwivedi A; Mehta A; Solanki P
    Indian J Pathol Microbiol; 2015; 58(4):453-8. PubMed ID: 26549066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.
    Lu TX; Miao Y; Wu JZ; Gong QX; Liang JH; Wang Z; Wang L; Fan L; Hua D; Chen YY; Xu W; Zhang ZH; Li JY
    Sci Rep; 2016 Feb; 6():20465. PubMed ID: 26857366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Gutiérrez-García G; Cardesa-Salzmann T; Climent F; González-Barca E; Mercadal S; Mate JL; Sancho JM; Arenillas L; Serrano S; Escoda L; Martínez S; Valera A; Martínez A; Jares P; Pinyol M; García-Herrera A; Martínez-Trillos A; Giné E; Villamor N; Campo E; Colomo L; López-Guillermo A;
    Blood; 2011 May; 117(18):4836-43. PubMed ID: 21441466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
    Oh S; Koo DH; Suh C; Kim S; Park BH; Kang J; Huh J
    J Korean Med Sci; 2011 Dec; 26(12):1556-62. PubMed ID: 22147991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.